Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Drugmaker Mylan NV's  merger with Pfizer Inc's  off-patent branded drug unit, Upjohn, would now close in the second half of 2020 due to the delays surrounding coronavirus, the companies said on Thursday.

Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

AbbVie

Allergan

Bristol-Myers

Eli Lilly

The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while.

3 Reasons Pharma Stocks Are a Buy Right Now

Bayer AG

FUJIFILM Holdings Corp

Gilead Sciences

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

These drugs could be key to staving off COVID-19 until a vaccine is developed.

All the Drugs Proving Anecdotally Effective Against COVID-19, and the Companies That Make Them

Amneal Pharmaceuticals

Novartis

Teva Pharmaceutical

No, but doctors can still use the drugs despite limited evidence of their effectiveness.

Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?

Boeing

Carnival

Moderna

The pursuit of a COVID-19 vaccine and antiviral therapies, the Defense Production Act, and using cruise ships as makeshift hospitals were among the topics covered in the briefing.

Trump’s Coronavirus News Conference on Thursday: 3 Key Things That Investors Should Know

Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus

The decades-old malaria drug could help fight the new coronavirus.

Mylan Ramps Up Production of Hydroxychloroquine as a Potential COVID-19 Treatment

Shares of Mylan MYL, +4.97% were up 6% in trading on Thursday after the drugmaker restarted production of hydroxychloroquine-sulfate tablets, which are being considered as a possible treatment for people with COVID-19.

Mylan to restart production of hydroxychloroquine

Biogen

BioMarin Pharmaceutical

Emergent BioSolutions

Momenta Pharmaceuticals

Novavax

An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.

Why These Drug Stocks Soared Today

Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.

Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply

When Mylan N.V. (NASDAQ: MYL) reported its fourth-quarter financial results after the markets closed on Thursday, the firm said that it had $1.40 in earnings per share (EPS) and $3.19 billion in revenue.

Are Mylan Results Enough for Investors?

Apologies, but we were unable to find what you were looking for. Perhaps  searching will help.

Are Mylan (MYL) Results Enough for Investors?

Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.

Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates

Mylan's (MYL) CEO Heather Bresch on Q4 2019 Results - Earnings Call Transcript

A 2014 deal the company made continued to pay off, while sales overseas were relatively strong.

Mylan Q4 Beats on Sales, Misses on EPS

Drugmaker Mylan NV  said on Thursday it expects the coronavirus outbreak to impact its financial results and warned of drug shortages in case of continued spread of the virus, sending shares of the company down 3.6%.

Mylan warns of possible drug shortages, financial hit due to coronavirus

Mylan (MYL) delivered earnings and revenue surprises of 8.53% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Tops Q4 Earnings Estimates

Drugmaker Mylan NV  reported a fourth-quarter profit on Thursday that beat estimates, helped by sales of new products such as asthma treatment Wixela.

Mylan quarterly profit beats estimates

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

3 Best Drugmakers That Are Immune to Coronavirus Fright

Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?

GlaxoSmithKline

Approvals were down slightly year over year.

FDA Approved 1,014 Generic Drugs in 2019

Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.

Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

Mylan Looks Attractive Heading Into Merger With Pfizer's Upjohn

Regulators are trying their best to help encourage competition, particularly in the biosimilars market.

The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News for Mylan Stock (MYL)